Authors
Junfeng Qi, Longzhu Xiong, Chuansha Wu, Xiaojie Sun, Junlin Li, Likun Ren, Chaoliang Yi, Yuqin Shi, Ling Zhang, Xiongfei Pan, Ting Zhou, Shuzhen Zhu
Published in
Obesity (Silver Spring, Md.). Jul 31, 2026. Epub Jul 31, 2026.
Abstract
This study aimed to explore personalized weight-loss targets for metabolic syndrome (MetS) reversal by introducing the BMI-normalization achievement rate (BMI-NAR), a novel baseline-BMI-scaled metric.
In a longitudinal cohort of 7340 adults with overweight/obesity and MetS from the ChinaHEART project, BMI-NAR was defined as the percentage of progress toward a normal BMI (< 24 kg/m2). Logistic regression and restricted cubic splines assessed the dose-response relationship between BMI-NAR and MetS reversal.
Each 50% increase in BMI-NAR was significantly associated with MetS reversal (overall: OR = 1.10, 95% CI: 1.07-1.12; overweight: OR = 1.08, 95% CI: 1.06-1.11; obesity: OR = 2.36, 95% CI: 2.00-2.80). The probability of reversal increased steeply beyond exploratory minimum effective thresholds (37% BMI-NAR for overall; 53% for overweight; 22% for obesity), with benefits observed up to ~165% in the total population, beyond which data were sparse. No clear upper plateau was identified in populations with overweight and obesity. These exploratory thresholds translate into personalized weight-loss targets: a minimum reduction of 2%-8% for typical overweight (baseline BMI 25-27.99 kg/m2) and 3%-9% for obesity.
MetS reversal does not require full BMI normalization. BMI-NAR provides a hypothesis-generating, quantifiable framework for exploring personalized minimum effective weight-loss goals in this high-risk population. However, external validation is required before clinical application.
PMID:
42538314
Bibliographic data and abstract were imported from PubMed on 01 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 19
- Comments 0